2nd April 2019
European Commission grants Marketing Authorization for Ajovy
Ajovy has been submitted for a NICE technology appraisal
The European Commission has granted Marketing Authorization for Ajovy (fremanezumab), a calcitonin gene-related peptide (CGRP) inhibitor that is manufactured by Teva.
This means that Ajovy, one of a new generation of migraine treatments, the first preventive medication that is dedicated to treating the condition, will be available privately in the UK.
It is the first and only anti-CGRP drug approved so far in the European Union that is designed for the prevention of migraine that offers both quarterly and monthly dosing options for the preventive treatment of migraine.
Teva has submitted it for a technology appraisal by the National Institute for Care and Health Excellent (NICE) for it to be available on the NHS. Its first committee meeting is due to take place on 22 October 2019.
The Migraine Trust welcomes the news and hopes it represents another step towards people living with migraine getting access to the best and most appropriate treatments on the NHS.